- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Programmed cell death protein 1 (PD-1) serves as an immune checkpoint that inhibits the T-cell response.1 PD-1 is activated when it is engaged by its ligands (PD-L1 or PD-L2), present on the antigen-presenting cell, resulting in inhibition of T-cell function.1 Early evidence suggests that tumors may co-opt this pathway by upregulating expression of PD-1 ligands as a mechanism of immune resistance.1 Therefore, targeting the PD-1/PD-L1 pathway is a promising immunotherapeutic strategy that may enhance T-cell anti-tumor responses.1-3